249 related articles for article (PubMed ID: 17971075)
1. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease.
Alegre-Abarrategui J; Ansorge O; Esiri M; Wade-Martins R
Neuropathol Appl Neurobiol; 2008 Jun; 34(3):272-83. PubMed ID: 17971075
[TBL] [Abstract][Full Text] [Related]
2. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.
Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R
Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310
[TBL] [Abstract][Full Text] [Related]
3. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.
Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V
Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743
[TBL] [Abstract][Full Text] [Related]
4. Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies.
Perry G; Zhu X; Babar AK; Siedlak SL; Yang Q; Ito G; Iwatsubo T; Smith MA; Chen SG
Neurodegener Dis; 2008; 5(3-4):222-4. PubMed ID: 18322396
[TBL] [Abstract][Full Text] [Related]
5. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology.
Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R
Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128
[TBL] [Abstract][Full Text] [Related]
6. Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease.
Higashi S; Moore DJ; Yamamoto R; Minegishi M; Sato K; Togo T; Katsuse O; Uchikado H; Furukawa Y; Hino H; Kosaka K; Emson PC; Wada K; Dawson VL; Dawson TM; Arai H; Iseki E
J Neuropathol Exp Neurol; 2009 Sep; 68(9):994-1005. PubMed ID: 19680143
[TBL] [Abstract][Full Text] [Related]
7. LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models.
Guerreiro PS; Huang Y; Gysbers A; Cheng D; Gai WP; Outeiro TF; Halliday GM
J Mol Med (Berl); 2013 Apr; 91(4):513-22. PubMed ID: 23183827
[TBL] [Abstract][Full Text] [Related]
8. Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.
Daher JP; Pletnikova O; Biskup S; Musso A; Gellhaar S; Galter D; Troncoso JC; Lee MK; Dawson TM; Dawson VL; Moore DJ
Hum Mol Genet; 2012 Jun; 21(11):2420-31. PubMed ID: 22357653
[TBL] [Abstract][Full Text] [Related]
9. LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions.
Huang Y; Song YJ; Murphy K; Holton JL; Lashley T; Revesz T; Gai WP; Halliday GM
Acta Neuropathol; 2008 Dec; 116(6):639-46. PubMed ID: 18936941
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau.
Taymans JM; Cookson MR
Bioessays; 2010 Mar; 32(3):227-235. PubMed ID: 20127702
[TBL] [Abstract][Full Text] [Related]
11. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and pathological characterization of Lrrk2.
Giasson BI; Covy JP; Bonini NM; Hurtig HI; Farrer MJ; Trojanowski JQ; Van Deerlin VM
Ann Neurol; 2006 Feb; 59(2):315-22. PubMed ID: 16437584
[TBL] [Abstract][Full Text] [Related]
13. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
Henderson MX; Peng C; Trojanowski JQ; Lee VMY
Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
[TBL] [Abstract][Full Text] [Related]
14. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.
Arima K; Hirai S; Sunohara N; Aoto K; Izumiyama Y; Uéda K; Ikeda K; Kawai M
Brain Res; 1999 Oct; 843(1-2):53-61. PubMed ID: 10528110
[TBL] [Abstract][Full Text] [Related]
15. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease.
Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY
Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655
[TBL] [Abstract][Full Text] [Related]
16. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease.
Vitte J; Traver S; Maués De Paula A; Lesage S; Rovelli G; Corti O; Duyckaerts C; Brice A
J Neuropathol Exp Neurol; 2010 Sep; 69(9):959-72. PubMed ID: 20720502
[TBL] [Abstract][Full Text] [Related]
17. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.
Wakabayashi K; Tanji K; Mori F; Takahashi H
Neuropathology; 2007 Oct; 27(5):494-506. PubMed ID: 18018486
[TBL] [Abstract][Full Text] [Related]
18. The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies.
Seidel K; Mahlke J; Siswanto S; Krüger R; Heinsen H; Auburger G; Bouzrou M; Grinberg LT; Wicht H; Korf HW; den Dunnen W; Rüb U
Brain Pathol; 2015 Mar; 25(2):121-35. PubMed ID: 24995389
[TBL] [Abstract][Full Text] [Related]
19. G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.
Volpicelli-Daley LA; Abdelmotilib H; Liu Z; Stoyka L; Daher JP; Milnerwood AJ; Unni VK; Hirst WD; Yue Z; Zhao HT; Fraser K; Kennedy RE; West AB
J Neurosci; 2016 Jul; 36(28):7415-27. PubMed ID: 27413152
[TBL] [Abstract][Full Text] [Related]
20. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.
Lin X; Parisiadou L; Gu XL; Wang L; Shim H; Sun L; Xie C; Long CX; Yang WJ; Ding J; Chen ZZ; Gallant PE; Tao-Cheng JH; Rudow G; Troncoso JC; Liu Z; Li Z; Cai H
Neuron; 2009 Dec; 64(6):807-27. PubMed ID: 20064389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
